Abstract

Encorafenib and cetuximab is efficient in anti-EGFR-naïve patients (pts) with BRAFV600E mutated (BRAFm) metastatic colorectal cancer (mCRC) after failure of one or two prior lines of treatment (BEACON trial). However to date, the efficacy of BRAF inhibitors in combination with anti-EGFRs (B+E) in patients (pts) previously treated with an anti-EGFR agent has never been reported.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call